The nature, time course and severity of methamphetamine withdrawal

Discipline of Clinical and Experimental Pharmacology, University of Adelaide, Tarndarnya, South Australia, Australia
Addiction (Impact Factor: 4.74). 10/2005; 100(9):1320-9. DOI: 10.1111/j.1360-0443.2005.01160.x
Source: PubMed


To characterize the natural history of methamphetamine withdrawal during the first 3 weeks of abstinence.
Cross-sectional study with comparison group. Setting A substance use treatment facility in Chiang Mai Province, Thailand.
The sample comprised 21 in-patients undergoing treatment for methamphetamine dependence. Nine age- and sex-matched non-dependent individuals provided comparison data.
Instruments including: the Amphetamine Withdrawal Questionnaire, a modified version of the Cocaine Selective Severity Assessment, Clinical Global Impression scale and the St Mary's Hospital Sleep Questionnaire were completed daily for the first 3 weeks of abstinence.
Methamphetamine withdrawal severity declined from a high initial peak within 24 hours of the last use of amphetamines reducing to near control levels by the end of the first week of abstinence (the acute phase). The acute phase of amphetamine withdrawal was characterized by increased sleeping and eating, a cluster of depression-related symptoms and less severely, anxiety and craving-related symptoms. Following the acute withdrawal phase most withdrawal symptoms remained stable and at low levels for the remaining 2 weeks of abstinence.
This study has provided evidence of a methamphetamine withdrawal syndrome that can be categorized into two phases, the acute phase lasting 7-10 days during which overall symptom severity declined in a linear pattern from a high initial peak, and a subacute phase lasting at least a further 2 weeks.

Download full-text


Available from: Manit Srisurapanont,
    • "Some patients with paranoid states will need to remain in hospital for months, and despite of abstinence from the stimulant and treatment with antipsychotic drugs, symptoms tend to persist in a few subjects (Iwanami et al., 1994). Withdrawal period can be subjectively highly distressing but not a life-threatening condition (McGregor et al., 2005; Scott et al., 2007; Watson, Hartmann, & Schildkraut, 1972). Depression, fatigue, insomnia "
    [Show abstract] [Hide abstract]
    ABSTRACT: Administration of amphetamine and methamphetamine can elicit psychiatric adverse effects at acute administration, binge use, withdrawal, and chronic use. Most troublesome of these are psychotic states and aggressive behavior, but a large variety of undesirable changes in cognition and affect can be induced. Adverse effects occur more frequently with higher dosages and long-term use. They can subside over time but some persist long-term. Multiple alterations in the gray and white matter of the brain assessed as changes in tissue volume or metabolism, or at molecular level, have been associated with amphetamine and methamphetamine use and the psychiatric adverse effects, but further studies are required to clarify their causal role, specificity, and relationship with preceding states and traits and comorbidities. The latter include other substance use disorders, mood and anxiety disorders, attention deficit hyperactivity disorder, and antisocial personality disorder. Amphetamine- and methamphetamine-related psychosis is similar to schizophrenia in terms of symptomatology and pathogenesis, and these two disorders share predisposing genetic factors. © 2015 Elsevier Inc. All rights reserved.
    International Review of Neurobiology 12/2015; 120:179-204. DOI:10.1016/bs.irn.2015.02.004 · 1.92 Impact Factor
  • Source
    • "Methamphetamine (METH) is a potent psychostimulant for dependence [23] with neurotoxic properties [7]. METH dependence is associated with a number of withdrawal symptoms after METH cessation including depression and anxiety after 2–3 days of abstinence in human [19] and animal models of anxiety using the EPM [22] and depression using the FST [24], stereotyped behavior, locomotor activity such as vertical rearing behavior in rats [10] and weight loss in humane [9]. The acute withdrawal symptoms last 7–10 days, and chronic phase associated with neurotoxicity effects may persist for several months. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to examine the effect of environmental enrichment during METH administration on the behavioral withdrawal symptoms after drug abstinence in rats. Rats reared in standard (SE) or enriched environment (EE) during induction of METH dependence with bi-daily injections of METH (2mg/kg, at 12- hr. intervals) for 14 days. Then, rats were evaluated for behavioral withdrawal symptoms, and also for anxiety (Elevated plus maze-EPM) and depression (Forced swim test-FST) over a ten day period of abstinence. The results showed that stereotypic behaviors score and the number of rearing were significantly lower in METH/EE rats compared to the SE group during 1-4 days. Also, The METH/EE group exhibited more weight gain during 6-10 days of abstinence. The METH/EE rats exhibited lower levels of immobility after METH abstinence than control group in the FST. EE had no effect on anxiety-like behavior. This study showed that exposure to EE diminished the severity of withdrawal symptoms and depressive-like behavior during spontaneous withdrawal from METH. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Neuroscience Letters 08/2015; 605. DOI:10.1016/j.neulet.2015.08.010 · 2.03 Impact Factor
  • Source
    • "These adaptations manifest as dysphoria and anhedonia when the drug is withdrawn, motivating further substance use to " self-medicate " this reward deficit. Consistent with this model, there is evidence from human studies that anhedonia increases following the onset of substance abuse (Bovasso, 2001), predicts increased likelihood of relapse in dependent users attempting to quit (Cook, Spring, McChargue, & Doran, 2010; Leventhal, Waters, Kahler, Ray, & Sussman, 2009), and declines over time with successful abstinence in those recovering from substance dependence (Dawes, Sitharthan, Conigrave, Phung, & Weltman, 2011; Dawkins, Powell, Pickering, Powell, & West, 2009; Martinotti et al., 2011; McGregor et al., 2005; Newton, Kalechstein, Duran, Vansluis, & Ling, 2004). Taken together, these findings suggest that impaired reward responsiveness is likely to emerge alongside the development of a substance use disorder, and may diminish with abstinence. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Attenuated responses to natural rewards have been found to predict subsequent substance use among dependent populations, suggesting that this may be a premorbid risk factor for later problematic substance use. However, research on adolescent risk-taking suggests that exaggerated, rather than blunted, reward responsiveness predicts later substance abuse. Acoustic startle-induced event-related potentials (ERP) were recorded in a sample of 11-13 year-olds while they viewed affective pictures, and participants were reassessed four years later regarding alcohol use and experience of alcohol-related problems. Increased attenuation of the amplitude of the P300 component of the ERP during viewing of pleasant pictures, relative to amplitude during neutral pictures (an indicator of increased attention to pleasant pictures), predicted increased likelihood of alcohol-related problems at follow-up. These findings further support research indicating that increased reward responsiveness predicts risky behaviours in adolescence, with anhedonia primarily a consequence of substance dependence. Copyright © 2015. Published by Elsevier B.V.
    Biological psychology 03/2015; 108. DOI:10.1016/j.biopsycho.2015.03.014 · 3.40 Impact Factor
Show more